IASLC > International Association for the Study of Lung Cancer > Conferences & Events > Event Details
IASLC Atlas of PD-L1 Testing in Lung Cancer
November 09, 2017 | Online


The IASLC Atlas of PD-L1 Immunohistochemistry Testing in Lung Cancer is a new resource for understanding programmed cell death ligand-1 (PD-L1) immunohistochemistry (IHC) assays. It is designed to help pathologists, clinicians, other health care personnel and patients better understand emerging programmed cell death ligand-1 (PD-L1) immunohistochemistry (IHC) assays.

What you should expect to learn

After viewing this program attendees will:

  • Recognize the selection and use of IHC testing;
  • Employ the Atlas of P-L1 IHC Testing as a resource for diagnosis and treatment options;
  • Identify the changing landscape of laboratory testing and current information about emerging PD-L1 assays.

Ming-Sound Tsao, MD, FRCPC

Senior Scientist
Princess Margaret Cancer Center\Professor of Laboratory Medicine and Pathology
M. Qasim Choski Chair in Lung Cancer Translational Research
University of Toronto, Canada